Reactivity of CD8+ T cells from patients with other hematopoietic or non-hematopoietic tumors to test peptides
. | . | PR1 . | . | . | WT1 . | . | . | BCR-ABL . | . | . | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
UPN . | Diagnosis . | 0.1 μM . | 1 μM . | 10 μM . | 0.1 μM . | 1 μM . | 10 μM . | 0.1 μM . | 1 μM . | 10 μM . | ||||||
154 | RCC | — | — | ND | — | — | — | — | ND | ND | ||||||
167 | RCC | — | — | — | — | ND | — | — | — | — | ||||||
209 | RCC | — | — | — | — | — | — | — | — | — | ||||||
214 | RCC | — | — | — | — | — | — | — | — | — | ||||||
215 | Sarcoma | — | — | — | — | — | — | — | — | — | ||||||
52 | RAEBT | — | — | — | — | — | — | — | — | — | ||||||
187 | CMML | ND | ND | ND | — | ND | — | ND | ND | ND | ||||||
227 | MDS | ND | ND | ND | — | ND | — | ND | ND | ND | ||||||
350 | RAEBT | 29.9 | 8.8 | 6.3 | 11 | 5.6 | 4.3 | — | — | — | ||||||
PT 3 | MDS | — | ND | ND | — | — | — | ND | ND | ND | ||||||
PT 4 | RA | ND | ND | ND | — | — | — | ND | ND | ND |
. | . | PR1 . | . | . | WT1 . | . | . | BCR-ABL . | . | . | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
UPN . | Diagnosis . | 0.1 μM . | 1 μM . | 10 μM . | 0.1 μM . | 1 μM . | 10 μM . | 0.1 μM . | 1 μM . | 10 μM . | ||||||
154 | RCC | — | — | ND | — | — | — | — | ND | ND | ||||||
167 | RCC | — | — | — | — | ND | — | — | — | — | ||||||
209 | RCC | — | — | — | — | — | — | — | — | — | ||||||
214 | RCC | — | — | — | — | — | — | — | — | — | ||||||
215 | Sarcoma | — | — | — | — | — | — | — | — | — | ||||||
52 | RAEBT | — | — | — | — | — | — | — | — | — | ||||||
187 | CMML | ND | ND | ND | — | ND | — | ND | ND | ND | ||||||
227 | MDS | ND | ND | ND | — | ND | — | ND | ND | ND | ||||||
350 | RAEBT | 29.9 | 8.8 | 6.3 | 11 | 5.6 | 4.3 | — | — | — | ||||||
PT 3 | MDS | — | ND | ND | — | — | — | ND | ND | ND | ||||||
PT 4 | RA | ND | ND | ND | — | — | — | ND | ND | ND |
UPN indicates unique patient number; RCC, renal cell carcinoma; ND, not done; RAEBT, refractory anemia with excess blasts in transformation; CMML, chronic myelomonocytic leukemia; MDS, myelodysplastic syndrome; and RA, refractory anemia. Stimulation indices scored as (—) represent reactivities < 2 over background.